Menu
Logo

First approved CD38-targeting monoclonal antibody for multiple myeloma

See which of your patients are suitable for DARZALEX®

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
Prof. van de Donk discusses the multiple mechanisms of action of DARZALEX®

In this video, Prof. Niels van de Donk of VU University Medical Center, Amsterdam, briefly discusses the multiple mechanisms of action of DARZALEX® and how the drug promotes myeloma and immunosuppressor cell death, leading to durable anti-tumour responses

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
A powerful mechanism of action

View an animation that demonstrates the multifaceted mode of action of DARZALEX® – the first approved CD38-targeting monoclonal antibody for MM

MM: multiple myeloma

Para visualizar o IECRCM de Darzalex, veja aqui.
CP-287814 - março 2022
Este site foi publicado pela Janssen-Cilag Farmacêutica, Lda. - que é a única responsável pelo seu conteúdo. Este site é dirigido a residentes em Portugal. Janssen-Cilag Farmacêutica, Lda. | Lagoas Park, Edifício 9, 2740-262 Porto Salvo | www.janssen.com/portugal |Sociedade por quotas | Matriculada na Conservatória do Registo Comercial de Oeiras, sob nº 10576 | Capital Social €2.693.508,64 | Nº Contribuinte 500 189 412
Aviso LegalPolìtica de PrivacidadePolítica de Cookies
Definição de Cookies
Logo